Acino ? Delivering Health
Acino ? Delivering Health
Acino ? Delivering Health
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Development projects<br />
Rivastigmine TDS 1 day<br />
Characteristics<br />
– Indication: Symptomatic treatment of mild to moderate Alzheimer dementia<br />
– Transdermal system for 1 day application<br />
– 2 strengths: 4.6 mg/24 h and 9.5 mg/24 h<br />
<strong>Acino</strong>'s timeline for target markets EU and US<br />
– EU: Day 106 granted, launch expected Q1-2013<br />
– US: ANDA accepted, launch expected Q1-2016 (depending on ANDA litigation)<br />
Reference product<br />
– Exelon ® Patch (Novartis)<br />
Competitor situation<br />
– SK Chemicals Korea expect launch in EU in Q1-2013<br />
Life cycle management activities<br />
– Development of additional higher strength (13.3 mg/24 h) ongoing<br />
22
Change language